Piper Jaffray Raises Price Target on Cantel Medical (CMN) Following 3Q15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cantel Medical Reports Results For The Third Quarter Ended April 30, 2015
June 9, 2015 8:01 AM EDTLITTLE FALLS, N.J., June 9, 2015 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN) reported US GAAP net income of $12,356,000, or $0.30 per diluted share, on an 18% increase in sales to a record $141,508,000 for the third quarter ended April 30, 2015. This compares with net income of $10,249,000, or $0.25 per diluted share, on sales of $120,058,000 for the third quarter ended April 30, 2014. For the nine months ended April 30, 2015, the Company reported US GAAP net income of $34,680,000, or $0.83 per diluted share, on a 16% increase in sales to a record $413,749,000. This compares with net income of $32,560,000 or $0.79 per diluted... More
